コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 If the patient is experiencing pain or suffering, treatment t
2 If the patients' exposure times are long enough to evaluate s
3 coming RN did not know the patient (F(1,155)=6.51, p=<.05), if the patient was expected to die during the shift (F(1,155)
4 a surgical procedure (n = 42,143) or medical (n = 149,137) if the patient did not receive surgical treatment in the last
5 tality before hospital discharge home or until study day 60 if the patient was still in a health care facility.
6 d 1 (PD-L1) expression, pembrolizumab should be used alone; if the patient has low PD-L1 expression, clinicians should of
7 er the initial specimen was also retrieved if available and if the patient had not yet been transferred to the intensive
8 icipant, we determined how mean deviation (MD) would change if the patient maintains his/her IOP at 1 of 7 levels (6, 9,
9 Substitutions must be followed by control visits to check if the patient is taking the medication correctly and if drug
10 rmulation is more convenient, and could still be considered if the patient has a strong preference or if difficulties occ
11 onse was defined prospectively as successful rhythm control if the patient remained on the same AAD therapy for a minimum
12 formed at baseline, after two cycles (and after four cycles if the patient was PET-positive after two cycles), and at the
13 We undertook this study to determine if the patient's metabolic fingerprint prior to therapy could
14 atient, our data support selecting a CMV-seropositive donor if the patient receives a myeloablative conditioning regimen.
15 ibacterial prophylaxis with cefazolin sodium (or other drug if the patient was allergic to cefazolin).
16 CE 6: Clinicians should pursue evaluation of hematuria even if the patient is receiving antiplatelet or anticoagulant the
17 patients with coronary artery disease requiring DAPT, even if the patients are on low-dose aspirin.
18 reated effectively and good visual outcomes can be expected if the patient is treated in time with anterior chamber injec
19 ations, and as we see through history, this may only happen if the patient believes there is an actual neuromodulatory ef
21 8-fold higher if patients were aged <5 years, 5-fold higher if the patient had any evidence of bleeding, and 5.2-fold hig
24 or implantable cardioverter-defibrillator (ICD) (the latter if the patient had an indication for defibrillation therapy)
26 e FOM, the concordance across all treatment plans was lower if the patients had ADT claims within 180 d before NaF PET.
27 g dose was 60 mg/day orally but could be escalated to 80 mg if the patient did not experience a response.
29 cerebellar ataxia (odds ratio, 10.5; 95% CI, 3.2-34.5), or if the patient had coexisting neuronal cell-surface antibodie
30 ad a secondary ICD-9-CM diagnosis code for Crohn disease or if the patient was not continuously enrolled in an insurance
31 e tumor lacked MLH1 expression and was also BRAF mutated or if the patient was diagnosed at age greater than 72 years and
32 associated with greater self-care management, particularly if the patient's emotional state was negative, and their unde
33 One consideration has been to deny payment if the patient's diagnosis upon ED discharge appears to refle
34 (if not previously administered) and may offer pertuzumab, if the patient has not previously received it.
37 approach beginning with more simple care that is progressed if the patient does not respond, and the use of simple risk p
38 ecommend a tracheostomy (1.38 [1.35-1.41]) and reintubation if the patient failed extubation (1.87 [1.81-1.94]).
39 l carcinoma (without positive markers, eg, EGFR/ALK /ROS1), if the patient has high programmed death ligand 1 (PD-L1) exp
40 experienced less burden in terms of disruption to schedule if the patient received the intervention (P = .05).
41 use medical therapies over a defined period of time to see if the patient improves or deteriorates according to agreed-u
42 after a first unprovoked proximal DVT or PE is strengthened if the patient is male, the index event was PE rather than DV
43 Treatment outcomes were defined as successful if the patient was cured or completed treatment and unsuccess
45 Outcomes were considered successful if the patients had deviations less than 10 prism diopters (P
46 should be considered, by comparing the benefits of surgery if the patient has lung cancer with the potential harm if the
47 the risk of tumor transmission with the chances of survival if the patient waits for another offer of a transplant.
48 information found lower failure to receive glucose testing if the patient received care at a CMHC (0.74 [0.64-0.85]) or
49 e patient was cured or completed treatment and unsuccessful if the patient died or defaulted from treatment or if treatme
50 CI, 5.0-15.8) and varied based on the following variables: if the patient was on complex care service (5.3 minutes [95%
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。